11,567 results match your criteria Journal of cardiovascular pharmacology[Journal]


Ligustilide ameliorates the permeability of the blood-brain barrier model in vitro during oxygen-glucose deprivation injury through HIF/VEGF pathway.

J Cardiovasc Pharmacol 2019 Mar 6. Epub 2019 Mar 6.

Medical School, Western Sydney University, Penrith, NSW 2751, Australia.

Abstract Chuanxiong rhizome has been widely used for the treatment of cerebral vascular disease in traditional Chinese medicine. The integrity of blood-brain barrier (BBB) is closely linked to the cerebral vascular disease. The protective effects of ligustilide, the major bioactive component in Chuanxiong rhizome, on cerebral blood vessel has been reported previously, but its effects and potential mechanism on BBB has not been entirely clarified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000664DOI Listing
March 2019
2 Reads

Real Life Indications to Sacubitril/Valsartan Treatment in Patients with Chronic Systolic Heart Failure.

J Cardiovasc Pharmacol 2019 Mar 6. Epub 2019 Mar 6.

Heart Failure Clinic, Department of Clinical Cardiology, Ospedale San Raffaele, Milano, Italy.

Objective: International guidelines recommend the introduction of sacubitril/valsartan in patients with heart failure and reduced ejection fraction who remain symptomatic despite optimal up-titrated therapy. The purpose of the following analysis is to verify the real-life eligibility for sacubitril/valsartan in a population of patients suffering from chronic heart failure, regularly monitored in a single heart failure clinic and treated according to guideline-directed medical therapy.

Methods: From a total of 1070 patients regularly monitored in our HF Clinic between January-2011 and September-2017, the clinical records of 224 patients with heart failure and reduced ejection fraction on optimized guidelines directed medical therapy were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000665DOI Listing
March 2019
1 Read

Cyclodextrin ameliorates the progression of atherosclerosis via increasing HDL-C plasma levels and anti-inflammatory effects in rabbits.

J Cardiovasc Pharmacol 2019 Feb 26. Epub 2019 Feb 26.

Jilin Provincial Key Laboratory of Animal Embryo Engineering, College of Animal Sciences, Jilin University, Changchun, Jilin Province, China.

To investigate the therapeutic effects of cyclodextrin on the development of atherosclerosis in rabbits, we evaluated the effects of (2-hydroxypropyl)-β-cyclodextrin(HPβCD)therapy on the organ coefficient, lipid profiles, inflammatory cytokines and atherosclerotic plaques in rabbits fed a high-fat diet. Our results demonstrated that HPβCD therapy reduced plasma triglyceride levels and inflammatory cytokine levels but increased plasma high-density lipoprotein cholesterol (HDL-C) levels. HPβCD therapy produced a significant decrease in the atherosclerotic lesion area and reduced macrophage and collagen content in the lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000660DOI Listing
February 2019
6 Reads

Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late.

J Cardiovasc Pharmacol 2019 Apr;73(4):207-214

University of Campania "Luigi Vanvitelli," Monaldi Hospital, AORN Ospedali dei Colli, Naples, Italy.

Atrial fibrillation is the most common arrhythmia in clinical practice, and age is one of the strongest predictors/risk factors for ischemic stroke in patients with atrial fibrillation. Elderly patients, in particular patients aged 80 years and older, are at higher risk of both ischemic and bleeding events compared with younger patients. Vitamin K antagonists (VKAs) reduce the risk of ischemic stroke, especially in the elderly, but increase the bleeding risk. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000661DOI Listing

Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction.

J Cardiovasc Pharmacol 2019 Mar;73(3):195-205

Faculty of Veterinary Medicine, Tokyo University of Agriculture and Technology (TUAT), Tokyo, Japan.

Myocardial relaxation and stiffness are influenced by fibrillar collagen content. Cyclic nucleotide signaling regulators have been investigated targeting more effective modulation of collagen deposition during myocardial healing process. To assess the effects of phosphodiesterase type 3 and phosphodiesterase type 5 inhibitors on cardiac function and left ventricular myocardial fibrosis in catecholamine-induced myocardial injury, sildenafil and pimobendan were administered to male Wistar rats 24 hours after isoproterenol injection. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-201903000-0000
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000652DOI Listing
March 2019
4 Reads

Phenylephrine Attenuated Sepsis-Induced Cardiac Inflammation and Mitochondrial Injury Through an Effect on the PI3K/Akt Signaling Pathway.

J Cardiovasc Pharmacol 2019 Mar;73(3):186-194

Department of Pathophysiology, Key Laboratory of State Administration of Traditional Chinese Medicine of the People's Republic of China, School of Medicine, Jinan University, Guangzhou, Guangdong, China.

Objective: To investigate whether phenylephrine (PE) inhibits sepsis-induced cardiac dysfunction, cardiac inflammation, and mitochondrial injury through the PI3K/Akt signaling pathway.

Methods: A rat model of sepsis was established by cecal ligation and puncture. PE and/or wortmannin (a PI3K inhibitor) were administered to investigate the role of PI3K/Akt signaling in mediating the effects of PE on inhibiting sepsis-induced cardiac dysfunction, cardiac inflammation, and mitochondrial injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000651DOI Listing
March 2019
1 Read

Roles of Endothelin B Receptors and Endothelial Nitric Oxide Synthase in the Regulation of Pulmonary Hemodynamic in Cirrhotic Rats.

J Cardiovasc Pharmacol 2019 Mar;73(3):178-185

Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Introduction: Hepatopulmonary syndrome and portopulmonary hypertension are common complications of liver disorders. This study aimed to determine roles of ET-B receptors and endothelial-derived NO synthase in the regulation of pulmonary hemodynamic in cirrhotic rats.

Methods: Male Sprague-Dawley rats were divided into the Sham and common bile duct ligation (CBDL) groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000650DOI Listing
March 2019
9 Reads

2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury.

J Cardiovasc Pharmacol 2019 Mar;73(3):165-177

Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Estradiol may antagonize the adverse cardiovascular effects of angiotensin II (Ang II). We investigated the effects of 2-methoxyestradiol (2-ME), a nonestrogenic estradiol metabolite, on Ang II-induced cardiovascular and renal injury in male rats. First, we determined the effects of 2-ME on Ang II-induced acute changes in blood pressure, renal hemodynamics, and excretory function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000649DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404767PMC
March 2019
4 Reads

Effects of low-dose sacubitril/valsartan on different stages of cardiac hypertrophy in salt-loaded hypertensive rats.

J Cardiovasc Pharmacol 2019 Feb 28. Epub 2019 Feb 28.

. Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine.

Background: Sacubitril/valsartan was shown to attenuate the development of cardiac hypertrophy with enhanced blood pressure (BP) reduction compared to valsartan alone in animal models. We investigated whether a low dose sacubitril/valsartan has BP-independent effects on cardiac hypertrophy and pulmonary edema using a rat model of hypertension and obesity.

Methods And Results: In plan 1, male SHR/NDmcr-cp rats fed normal or phased-increased high salt were treated with vehicle, 6 mg/kg sacubitril/valsartan or 3 mg/kg valsartan, for 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000662DOI Listing
February 2019
4 Reads

Allopurinol administration for the prevention of contrast-induced nephropathy: a network meta-analysis with trial sequential analysis.

J Cardiovasc Pharmacol 2019 Feb 28. Epub 2019 Feb 28.

Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Athens University Medical School, National and Kapodistrian University of Athens, Greece.

Contrast-induced nephropathy represents a major source of morbidity in patients undergoing coronary angiography. Various preventive measures have been proposed, although the optimal one remains still unknown. The aim of the present meta-analysis is to accumulate current literature knowledge and evaluate the renoprotective effects of allopurinol administration prior to contrast medium exposure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000663DOI Listing
February 2019
1 Read

ALDH2 Activation Inhibited Cardiac Fibroblast-to-Myofibroblast Transformation Via the TGF-β1/Smad Signaling Pathway.

J Cardiovasc Pharmacol 2019 Apr;73(4):248-256

Medical Insurance Office, Qilu Hospital of Shandong University, Jinan, China.

Pathological stimulus-triggered differentiation of cardiac fibroblasts plays a major role in the development of myocardial fibrosis. Aldehyde dehydrogenase 2 (ALDH2) was reported to exert a protective role in cardiovascular disease, and whether ALDH2 is involved in cardiac fibroblast differentiation remains unclear. In this study, we used transforming growth factor-β1 (TGF-β1) to induce the differentiation of human cardiac fibroblasts (HCFs) and adopted ALDH2 activator Alda-1 to verify the influence of ALDH2 on HCF differentiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000655DOI Listing
April 2019
2 Reads
2.135 Impact Factor

Number of ECG Replicates and QT Correction Formula Influences the Estimated QT Prolonging Effect of a Drug.

J Cardiovasc Pharmacol 2019 Apr;73(4):257-264

Centre for Human Drug Research, Leiden, the Netherlands.

Introduction: The present analysis addressed the effect of the number of ECG replicates extracted from a continuous ECG on estimated QT interval prolongation for different QT correction formulas.

Methods: For 100 healthy volunteers, who received a compound prolonging the QT interval, 18 ECG replicates within a 3-minute window were extracted from 12-lead Holter ECGs. Ten QT correction formulas were deployed, and the QTc interval was controlled for baseline and placebo and averaged per dose level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000657DOI Listing
April 2019
1 Read

The NLRP3 Inflammasome Inhibitor, OLT1177 (Dapansutrile), Reduces Infarct Size and Preserves Contractile Function After Ischemia Reperfusion Injury in the Mouse.

J Cardiovasc Pharmacol 2019 Apr;73(4):215-222

VCU Pauley Heart Center, Richmond, VA.

Background: Activation of the NLRP3 inflammasome is a primary driver of sterile inflammation in response to myocardial ischemia reperfusion. Pharmacologic inhibitors of the NLRP3 inflammasome are being developed. We proposed that OLT1177 (dapansutrile), a novel NLRP3 inflammasome inhibitor, could preserve myocardial function after ischemia reperfusion injury in the mouse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000658DOI Listing

Prognostic Impact of Angiotensin Converting Enzyme Inhibitors and Receptor Blockers on Recurrent Ventricular Tachyarrhythmias and ICD Therapies.

J Cardiovasc Pharmacol 2019 Feb 8. Epub 2019 Feb 8.

First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, European Center for AngioScience (ECAS), and DZHK (German Center for Cardiovascular Research) partner site Heidelberg/Mannheim, Mannheim, Germany.

This study sought to assess the prognostic impact of treatment with angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) on recurrences of ventricular tachyarrhythmias in recipients of implantable cardioverter defibrillators (ICD).Using a large retrospective registry including consecutive ICD recipients with documented episodes of ventricular tachycardia (VT) or fibrillation (VF) from 2002 to 2016, those patients treated with ACEi/ARB were compared to patients without (non-ACEi/ARB). The primary prognostic endpoint was first recurrences of ventricular tachyarrhythmias and related ICD therapies at 5 years. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9856
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000659DOI Listing
February 2019
10 Reads
2.135 Impact Factor

Relationships of Statin Therapy and Hyperlipidemia With the Incidence, Rupture, Postrepair Mortality, and All-Cause Mortality of Abdominal Aortic Aneurysm and Cerebral Aneurysm: A Meta-analysis and Systematic Review.

J Cardiovasc Pharmacol 2019 Apr;73(4):232-240

Department of Obstetrics, Zaozhuang Municipal Hospital, Zaozhuang, China.

Statins have been suggested in previous studies to play a protective role in experimental cerebral aneurysm (CA) models; however, no evidence supports that the application of statins can protect against aneurysm rupture in humans, and the risks of lipid levels and aneurysms remain unknown. Therefore, this meta-analysis aimed to summarize and update the epidemiological evidence to systematically assess the relationships of statin therapy and hyperlipidemia with the incidence, rupture, postrepair mortality, and all-cause mortality of abdominal aortic aneurysm (AAA) and CA. Related studies were initially retrieved from the electronic databases PubMed, Embase, and Cochrane Library from inception to August 4, 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000653DOI Listing
April 2019
1 Read

Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation: Meta-analysis of Safety and Efficacy.

J Cardiovasc Pharmacol 2019 Apr;73(4):241-247

National United Engineering Laboratory for Biomedical Material Modification Branden Industrial Park, Dezhou, China.

Background: Radiofrequency ablation (RFA) and antiarrhythmic drugs (AADs) are the main treatments used for atrial fibrillation (AF). In recent years, a number of articles comparing the 2 treatments have begun to emerge. Though, the influence of follow-up time in the meta-analysis was not considered in these articles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000654DOI Listing
April 2019
5 Reads

Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.

J Cardiovasc Pharmacol 2019 Mar;73(3):127-135

Department of Cardiology, The First Affiliated Hospital, Jinan University, Guangzhou, China.

Aims: To evaluate the efficacy and safety of using genetic information to guide warfarin dosing in the Chinese population.

Methods: This meta-analysis was conducted among the published, randomized, controlled trials (RCTs) in the Chinese population comparing genotype-guided warfarin dosing (PG group) with clinical or standard warfarin dosing (STD group). RCTs published on or before January 2018 were identified using the PubMed, Embase, Cochrane Library, CNKI, Chinese VIP database, and Chinese Wanfang database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000656DOI Listing

A Novel and Highly Potent Urotensin II Receptor Antagonist Inhibits Urotensin II-Induced Pressure Response in Mice.

J Cardiovasc Pharmacol 2019 Jan;73(1):15-21

Rare Disease & LCM Laboratories, Daiichi-Sankyo Co, Ltd, Shinagawa-ku, Tokyo, Japan.

This study was designed to characterize the pharmacological profile of DS37001789, which is a structurally novel piperazine derivative that acts as urotensin II (U-II) receptor antagonist. DS37001789 inhibited [I]-U-II binding to human GPR14, U-II receptor, with an IC50 value 0.9 nM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000618DOI Listing
January 2019
17 Reads

Antihypertrophic Effects of Nebivolol on Neonatal Cardiomyocyte Hypertrophy Models.

Authors:
Isil Ozakca

J Cardiovasc Pharmacol 2019 Mar;73(3):155-164

Department of Pharmacology, Faculty of Pharmacy, Ankara University, Ankara, Turkey.

The antihypertrophic effect of nebivolol over cardioselective beta-blockers (β-blockers) is attributed to the activation of cardiac nitric oxide signaling. However, the precise role of nebivolol on hypertrophied cardiomyocytes remains unclear. In the current study, in vitro cardiomyocyte hypertrophy model was induced with isoprenaline (10 μM), angiotensin II (1 μM), and phenylephrine (20 μM) in neonatal cardiomyocytes isolated from 0- to 2-day-old Sprague-Dawley rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000647DOI Listing
March 2019
4 Reads

Efficacy of Minimally Invasive Intervention in Patients With Acute Cerebral Infarction.

J Cardiovasc Pharmacol 2019 Jan;73(1):22-26

Department of Neurosurgery, Shanxi Provincial People's Hospital, Taiyuan City, Shanxi Province, China.

Our aim was to explore the efficacy of minimally invasive intervention in patients with acute cerebral infarction (ACI). Seventy patients with ACI were randomized into either an experimental group or a control group. In addition to the regular treatment, patients in the control group also received intravenous thrombolysis with urokinase, while patients in the other group underwent percutaneous transluminal cerebral angioplasty and stenting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000625DOI Listing
January 2019
6 Reads

Atorvastatin Improves Doxorubicin-Induced Cardiac Dysfunction by Modulating Hsp70, Akt, and MAPK Signaling Pathways.

J Cardiovasc Pharmacol 2019 Apr;73(4):223-231

Department of Cardiology, The Second Hospital of Shandong University, Jinan, China.

Atorvastatin is a lipid-regulating drug that is commonly used in clinical practice and can stabilize plaques. Increasing evidence shows that statins have anti-heart failure (HF) effects, but their specific mechanism is not clear. The purpose of this study was to investigate the cardioprotective effects of atorvastatin on HF in rats and its mechanism. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9857
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000646DOI Listing
April 2019
3 Reads

Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.

J Cardiovasc Pharmacol 2019 Feb;73(2):118-124

Servicio de Cardiología, Hospital Universitario Gregorio Marañón, CIBERCV, Madrid, Spain.

Sacubitril/valsartan (SV) is a new therapy in heart failure with reduced ejection fraction. Our aim was to determine the efficacy and safety of this drug daily clinical practice. We performed a multicenter registry in 10 hospitals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000641DOI Listing
February 2019
33 Reads

Population Pharmacokinetic Analysis of Bisoprolol in Patients With Acute Coronary Syndrome.

J Cardiovasc Pharmacol 2019 Mar;73(3):136-142

Department of Pharmacology and Toxicology, Faculty of Medicine, University of Niš, Serbia.

To date, many questions about the extent and cause of pharmacokinetic (PK) variability of even the most widely studied and prescribed β1-adrenergic receptor blockers, such as metoprolol and bisoprolol, remain unanswered. Given that there are still no published population pharmacokinetic (PopPK) analyses of bisoprolol in routinely treated patients with acute coronary syndrome (ACS), the aim of this study was to determine its PK variability in 71 Serbian patients with ACS. PopPK analysis was conducted using a nonlinear mixed-effects model (NONMEM), version 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000644DOI Listing
March 2019
9 Reads

Comparison of Candesartan and Angiotensin-(1-7) Combination to Mito-TEMPO Treatment for Normalizing Blood Pressure and Sympathovagal Balance in (mREN2)27 Rats.

J Cardiovasc Pharmacol 2019 Mar;73(3):143-148

Hypertension & Vascular Research, Cardiovascular Sciences Center, Wake Forest University School of Medicine, Winston-Salem, NC.

Hypertensive transgenic (mRen2)27 rats exhibit impaired baroreflex sensitivity (BRS) for control of heart rate (HR). Intracerebroventricular infusion of Ang-(1-7) improves indices of vagal BRS independent of lowering mean arterial pressure (MAP), whereas AT1 receptor blockade normalizes MAP and indices of sympathetic tone without correcting the vagal BRS. Scavenging cellular reactive oxygen species (ROS) with tempol in brain fails to correct either hypertension or sympathovagal balance in these animals, despite reports that mitochondrial ROS contributes to Ang II-infusion hypertension. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9857
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000645DOI Listing
March 2019
15 Reads

Titration and Tolerability of Sacubitril/Valsartan for Patients With Heart Failure in Clinical Practice.

J Cardiovasc Pharmacol 2019 Mar;73(3):149-154

University of Alberta, Edmonton, Alberta, Canada.

Little is known about the dosing and tolerability of sacubitril/valsartan (LCZ696; Entresto, Quebec, Canada) in a nonclinical trial population. This study was conducted to evaluate the use and tolerability of sacubitril/valsartan in patients followed at a multidisciplinary heart failure (HF) clinic. We performed a retrospective chart review of 126 patients with HF, initiated on sacubitril/valsartan, and seen at a specialty HF clinic between August 1, 2015, and August 1, 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000643DOI Listing
March 2019
7 Reads

LongShengZhi Capsule Reduces Established Atherosclerotic Lesions in apoE-Deficient Mice by Ameliorating Hepatic Lipid Metabolism and Inhibiting Inflammation.

J Cardiovasc Pharmacol 2019 Feb;73(2):105-117

College of Biomedical Engineering, Hefei University of Technology, Hefei, China.

Disorders of lipid metabolism and inflammation play an important role in atherosclerosis. LongShengZhi (LSZ) capsule, a Chinese herbal medicine, has been used for treatment of patients with vascular diseases for many years. In this article, we determined the effect of LSZ on the progression of established atherosclerotic lesions in apoE-deficient (apoE) mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000642DOI Listing
February 2019
9 Reads

Therapeutic Drug Monitoring to Assess Drug Adherence in Assumed Resistant Hypertension: A Comparison With Directly Observed Therapy in Three Nonadherent Patients.

J Cardiovasc Pharmacol 2019 Feb;73(2):125

Department of Pharmacology, First Faculty of Medicine, General University Hospital in Prague, Charles University, Prague, Czech Republic. Supported by a Charles University project Progres Q25.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000637DOI Listing
February 2019
6 Reads

Mild Hypothermia Is Ineffective to Protect Against Myocardial Injury Induced by Chemical Anoxia or Forced Calcium Overload.

J Cardiovasc Pharmacol 2019 Feb;73(2):100-104

Cardiac Physiology, National Cerebral and Cardiovascular Center, Osaka, Japan.

Although hypothermia suppresses myocardial ischemia/reperfusion injury, whether it also protects the myocardium against cellular stresses such as chemical anoxia and calcium overload remains unknown. We examined the effect of mild hypothermia (33°C) on myocardial injury during ischemia/reperfusion, local administration of sodium cyanide (chemical anoxia), or local administration of maitotoxin (forced Ca overload) using cardiac microdialysis applied to the feline left ventricle. Baseline myoglobin levels (in ng/mL) were 237 ± 57 and 150 ± 46 under normothermia and hypothermia, respectively (mean ± SE, n = 6 probes each). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000639DOI Listing
February 2019
3 Reads

Panax Notoginseng Saponins Attenuate Myocardial Ischemia-Reperfusion Injury Through the HIF-1α/BNIP3 Pathway of Autophagy.

J Cardiovasc Pharmacol 2019 Feb;73(2):92-99

Cardiovascular Medicine, the Affiliated Hospital of Shaoxing University, Shaoxing, China.

Background And Objective: Panax Notoginseng Saponins (PNS) is a formula of Chinese medicine commonly used for treating ischemia myocardial in China. However, its mechanism of action is yet unclear. This study investigated the effect and the mechanism of PNS on myocardial ischemia-reperfusion injury (MIRI) through the hypoxia-inducible factor 1α (HIF-1α)/bcl-2/adenovirus E1B19kDa-interacting protein3 (BNIP3) pathway of autophagy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000640DOI Listing
February 2019
2 Reads

Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction.

J Cardiovasc Pharmacol 2019 Feb;73(2):82-91

Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis and Cardiovascular Functions, INSERM U1050/CNRS UMR7241, Center for Interdisciplinary Research in Biology, College de France, Paris, France.

Aims: Inhibition of brain angiotensin III by central infusion of aminopeptidase A (APA) inhibitor firibastat (RB150) inhibits sympathetic hyperactivity and heart failure in rats after myocardial infarction (MI). This study evaluated effectiveness of systemic treatment with firibastat compared with AT1R blocker, losartan.

Methods And Results: MI was induced by ligation of left coronary artery in male Wistar rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000638DOI Listing
February 2019
1 Read

Effect of Postablation Statin Treatment on Arrhythmia Recurrence in Patients With Paroxysmal Atrial Fibrillation.

J Cardiovasc Pharmacol 2018 Dec;72(6):285-290

2nd Department of Cardiology, University of Athens Medical School, Attikon Hospital, Athens, Greece.

Background: Statins have been proposed as a means to prevent postablation atrial fibrillation (AF) recurrences, mainly on the basis of their pleiotropic effects. The objective of this subanalysis of a prospectively randomized controlled study population of patients undergoing radiofrequency ablation for paroxysmal AF was to test the hypothesis that statin treatment is associated with longer time to recurrence.

Methods And Results: This is a subanalysis over an extended follow-up period of a prospective randomized study (ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000624DOI Listing
December 2018
6 Reads

Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.

J Cardiovasc Pharmacol 2019 Jan;73(1):3-14

Department of Anaesthesia and Intensive Care Medicine, San Gerardo Hospital, Monza, Italy.

Levosimendan is an inodilator that promotes cardiac contractility primarily through calcium sensitization of cardiac troponin C and vasodilatation via opening of adenosine triphosphate-sensitive potassium (KATP) channels in vascular smooth muscle cells; the drug also exerts organ-protective effects through a similar effect on mitochondrial KATP channels. This pharmacological profile identifies levosimendan as a drug that may have applications in a wide range of critical illness situations encountered in intensive care unit medicine: hemodynamic support in cardiogenic or septic shock; weaning from mechanical ventilation or from extracorporeal membrane oxygenation; and in the context of cardiorenal syndrome. This review, authored by experts from 9 European countries (Austria, Belgium, Czech republic, Finland, France, Germany, Italy, Sweden, and Switzerland), examines the clinical and experimental data for levosimendan in these situations and concludes that, in most instances, the evidence is encouraging, which is not the case with other cardioactive and vasoactive drugs routinely used in the intensive care unit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319595PMC
January 2019
3 Reads

Late Phases of Cardioprotection During Remote Ischemic Preconditioning and Adenosine Preconditioning Involve Activation of Neurogenic Pathway.

J Cardiovasc Pharmacol 2019 Feb;73(2):63-69

Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.

Background: The role of the neurogenic pathway in early phases of cardioprotection during remote ischemic preconditioning (RIPC) and adenosine preconditioning is reported.

Aim: This study was designed to explore the involvement of the neurogenic pathway in late phases of cardioprotection during RIPC and adenosine preconditioning.

Material And Methods: Fifty-four Wistar rats were used and divided into 9 experimental groups. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9858
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000634DOI Listing
February 2019
17 Reads
2.135 Impact Factor

Detection of Putative Functional Single Nucleotide Polymorphisms in Blood Pressure Loci and Validation of Association Between Single Nucleotide Polymorphism in WBP1L and Hypertension in the Chinese Han Population.

J Cardiovasc Pharmacol 2019 Jan;73(1):48-55

Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Soochow University, Suzhou, Jiangsu, China.

We have performed a gene-based association study and detected several important blood pressure (BP)-associated genes. In this study, we explored functional variants in these genes by bioinformatics analysis and validated the associations between the functional single nucleotide polymorphisms (SNPs) and hypertension with public data and our in-house data of 857 cases and 927 controls. We found various functional variants in the BP-associated genes, including missense mutations and phosphorylation-related SNPs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000633DOI Listing
January 2019
13 Reads

Mitochondrial Dysfunction and Apoptosis Are Attenuated on κ-Opioid Receptor Activation Through AMPK/GSK-3β Pathway After Myocardial Ischemia and Reperfusion.

J Cardiovasc Pharmacol 2019 Feb;73(2):70-81

Department of Physiology, National Key Discipline of Cell Biology, Fourth Military Medical University, Xi'an, China.

Previous studies have shown that κ-opioid receptor activation possesses cardioprotection against myocardial ischemia and reperfusion (MI/R) injury. The current study was designed to investigate whether mitochondrial dysfunction after MI/R is regulated by the κ-opioid receptor and to further explore the underlying mechanisms involved. MI/R rat model was established in vivo, and a hypoxia and reoxygenation cardiomyocytes model was used in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000635DOI Listing
February 2019
5 Reads
2.135 Impact Factor

An Orally Available NLRP3 Inflammasome Inhibitor Prevents Western Diet-Induced Cardiac Dysfunction in Mice.

J Cardiovasc Pharmacol 2018 Dec;72(6):303-307

VCU Pauley Heart Center, Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA.

Background: A diet rich in saturated fat and sugars (Western diet, WD) induces myocardial expression of the NLRP3 inflammasome and dysfunction in mice. We therefore hypothesized that a diet enriched with an orally available NLRP3 inflammasome inhibitor could prevent WD-induced cardiac dysfunction in mice.

Methods: Ten-week-old CD-1 male mice were fed WD or standard diet (SD) for 8 weeks. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-201812000-0000
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000628DOI Listing
December 2018
8 Reads

Combined Antihypertensive Therapies That Increase Expression of Cardioprotective Biomarkers Associated With the Renin-Angiotensin and Kallikrein-Kinin Systems.

J Cardiovasc Pharmacol 2018 Dec;72(6):291-295

Laboratory of Pharmacology and Laboratory of Infection Diseases, F.E.S.-Cuautitlan, Universidad Nacional Autonoma de Mexico, Cuautitlan Izcalli, Mexico.

Antihypertensive pharmacological treatments focus on the use of angiotensin-converting enzyme (ACE) inhibitors, AT1 receptor antagonists, and beta-blockers as single and combined treatments. The effect of single treatments on the mRNA expression of some components of the renin-angiotensin system has been studied, but not the effect of combined treatments. This study determined the expression of the AT1, AT2, B1, and B2 receptors and of the enzymes ACE and ACE2 in hypertensive rats treated with captopril-propranolol or losartan-propranolol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000629DOI Listing
December 2018
2 Reads

Investigating the Effect of Demographics, Clinical Characteristics, and Polymorphism of MDR-1, CYP1A2, CYP3A4, and CYP3A5 on Clopidogrel Resistance.

J Cardiovasc Pharmacol 2018 Dec;72(6):296-302

Department of Pharmacy Practice, Faculty of Pharmacy, Yarmouk University, Irbid, Jordan.

Clopidogrel is an antiplatelet agent that is indicated for cardiovascular emergencies and procedures. The drug, however, is subject to response variability leading to therapy resistance. In this research, we explored the demographic, clinical, and genetic factors associated with clopidogrel resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000627DOI Listing
December 2018
5 Reads

Melatonin Attenuates Cardiac Reperfusion Stress by Improving OPA1-Related Mitochondrial Fusion in a Yap-Hippo Pathway-Dependent Manner.

J Cardiovasc Pharmacol 2019 Jan;73(1):27-39

Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

The role of OPA1-related mitochondrial fusion in cardiac reperfusion stress has remained elusive. The aim of our study is to explore whether melatonin alleviates cardiac ischemia-reperfusion (IR) injury by modulating OPA1-related mitochondrial fusion. We found that melatonin reduced infarct area, sustained myocardial function, and suppressed cardiomyocyte death during cardiac reperfusion stress. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000626DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319588PMC
January 2019
7 Reads

Limited Impact of β-Adrenergic Receptor Activation on Left Ventricular Diastolic Function in Rat Models of Hypertensive Heart Disease.

J Cardiovasc Pharmacol 2018 Nov;72(5):242-251

Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Background: Hypertension is a major cause of left ventricular (LV) diastolic dysfunction. Although β-adrenergic receptor (β-AR) blockers are often used to manage hypertension, the impact of β-AR activation on LV lusitropic effects and hence filling pressures in the hypertensive heart with LV diastolic dysfunction is uncertain.

Methods: Using tissue Doppler imaging and Speckle tracking software, we assessed LV function in isoflurane anesthetised spontaneously hypertensive (SHR) and Dahl salt-sensitive (DSS) rats before and after β-AR activation [isoproterenol (ISO) administration]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000620DOI Listing
November 2018
7 Reads

Protective Action of Diazoxide on Isoproterenol-Induced Hypertrophy Is Mediated by Reduction in MicroRNA-132 Expression.

J Cardiovasc Pharmacol 2018 Nov;72(5):222-230

Departamento de Farmacología, Centro de Investigación y de Estudios Avanzados del IPN, Ciudad de México, México.

Introduction And Methods: The effects of diazoxide on cardiac hypertrophy and miR-132 expression were characterized in adult rats and in cardiomyocytes. Diazoxide effects on reactive oxygen species (ROS) production and on the cAMP-response element binding (CREB) transcription factor's abundance in cardiomyocytes were also analyzed. ROS measurements used a fluorescent dye. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000619DOI Listing
November 2018
11 Reads

Resveratrol Mitigates High-Fat Diet-Induced Vascular Dysfunction by Activating the Akt/eNOS/NO and Sirt1/ER Pathway.

J Cardiovasc Pharmacol 2018 Nov;72(5):231-241

Department and Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.

We investigated whether resveratrol (RSV) can attenuate obesity and diabetes progression and improve diabetes-induced vascular dysfunction, and we attempted to delineate its underlying mechanisms. Male C57Bl/6 mice were administered a high-fat diet (HFD) for 17 weeks. Mice developed type 2 diabetes with increased body weight, hyperglycemia, hyperinsulinemia, and hyperlipidemia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000621DOI Listing
November 2018
12 Reads

Seizing the Future: What's Next for the Journal of Cardiovascular Pharmacology?

Authors:
George W Booz

J Cardiovasc Pharmacol 2019 Jan;73(1):1-2

Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000630DOI Listing
January 2019
1 Read

Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.

J Cardiovasc Pharmacol 2019 Jan;73(1):56-59

Interventional Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, Spain.

Background: European Guidelines on Myocardial Revascularization recommend clopidogrel loading dose added to acetylsalicylic acid in elective percutaneous coronary interventions (PCIs). However, there is few evidence supporting this recommendation and other P2Y12 inhibitors have not been tested in these patients.

Purpose: To evaluate the effectiveness and safety of different loading doses of clopidogrel and ticagrelor in patients without double antiplatelet therapy and stable coronary artery disease (SCAD) undergoing elective PCI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000632DOI Listing
January 2019
8 Reads

Platelet Reactivity in Patients on Aspirin and Clopidogrel Therapy Measured by a New Bedside Whole-Blood Assay.

J Cardiovasc Pharmacol 2019 Jan;73(1):40-47

Institute of Transplantation Diagnostics and Cell Therapeutics, Heinrich Heine University Medical Centre Düsseldorf, Düsseldorf, Germany.

Various tests are available for measuring on-treatment platelet reactivity. The pharmacologically most specific assays are time-consuming and elaborate. A highly specific and convenient assay would be desirable for clinical routine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000631DOI Listing
January 2019
5 Reads

MicroRNA-18a Expression in Female Coronary Heart Disease and Regulatory Mechanism on Endothelial Cell by Targeting Estrogen Receptor.

J Cardiovasc Pharmacol 2018 Dec;72(6):277-284

Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Coronary heart disease (CHD) is a kind of cardiovascular disease, which has been causing mortality around the world for decades. Because symptoms of CHD are different in female and male patients and these symptoms occur much later in female patients, CHD is very likely to be underdiagnosed in women. Thus, it is imperative to explore novel diagnostic method for CHD especially for women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000623DOI Listing
December 2018
3 Reads

Aspirin Attenuates the Bioactivation of and Platelet Response to Vicagrel in Mice.

J Cardiovasc Pharmacol 2018 Nov;72(5):252-258

Department of Pharmacology, College of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

Vicagrel, a novel acetate analogue of clopidogrel, exerts more potent antiplatelet effect than clopidogrel in rodents. Relevant evidence indicated that aspirin and vicagrel are the drug substrate for carboxylesterase 2. Accordingly, it is deduced that concomitant use of aspirin could attenuate the bioactivation of and platelet response to vicagrel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000622DOI Listing
November 2018
3 Reads

Copaiba Oil Attenuates Right Ventricular Remodeling by Decreasing Myocardial Apoptotic Signaling in Monocrotaline-Induced Rats.

J Cardiovasc Pharmacol 2018 Nov;72(5):214-221

Department of Physiology, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Rio Grande do Sul, Brazil.

There is an increase in oxidative stress and apoptosis signaling during the transition from hypertrophy to right ventricular (RV) failure caused by pulmonary arterial hypertension (PAH) induced by monocrotaline (MCT). In this study, it was evaluated the action of copaiba oil on the modulation of proteins involved in RV apoptosis signaling in rats with PAH. Male Wistar rats (±170 g, n = 7/group) were divided into 4 groups: control, MCT, copaiba oil, and MCT + copaiba oil. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00005344-900000000-9859
Publisher Site
http://dx.doi.org/10.1097/FJC.0000000000000617DOI Listing
November 2018
8 Reads

Metformin Regulates the Expression of SK2 and SK3 in the Atria of Rats With Type 2 Diabetes Mellitus Through the NOX4/p38MAPK Signaling Pathway.

J Cardiovasc Pharmacol 2018 Nov;72(5):205-213

Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, China.

We previously found that metformin regulates the ion current conducted by the small conductance calcium-activated potassium channels (SK channels) in the atria of rats with type 2 diabetes mellitus (T2DM) as well as the mRNA and protein expression of the SK2 and SK3 subtypes of SK channels. In this study, we hypothesized that the nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4)/p38 mitogen-activated protein kinase (p38MAPK) signaling pathway was involved in the metformin-mediated regulation of SK2 and SK3 expression in the atria of rats with T2DM. We randomly divided Wistar rats into the control group, the untreated T2DM group, the metformin-treated group, the group receiving subcutaneous injections of the nicotinamide adenine dinucleotide phosphate oxidase (NOX) inhibitor diphenyleneiodonium (DPI), and the group receiving tail vein injections of the p38MAPK agonist anisomycin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FJC.0000000000000615DOI Listing
November 2018
4 Reads